I'rom Group Co., Ltd. is a Japanese enterprise specializing in several key areas: pioneering advanced medical treatments, offering site management organization (SMO) services, acting as a contract research organization (CRO), and providing various forms of medical support. The company spearheads the creation of cutting-edge medical technologies, particularly in regenerative medicine and gene therapy, to combat conditions like obstructive arteriosclerosis, retinitis pigmentosa, and HIV/AIDS. Their innovative contributions include the Sendai virus vector and the CytoTune-iPS kit, designed for generating induced pluripotent stem cells. Furthermore, I'rom assists medical institutions with clinical trial execution and delivers extensive support for the development of novel drugs and medical equipment, with a focus on cancer, rare, and intractable diseases. The company also oversees the establishment and operation of clinic malls. Founded in Tokyo in 1997, it was formerly known as I'Rom Holdings Co., Ltd. until its name change in July 2015.